Literature DB >> 26548757

Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

Giandomenico Roviello1, Daniele Generali.   

Abstract

It was estimated that small cell lung cancer (SCLC) accounts for about one Sixth of all lung cancer cases. Patients with SCLC are usually diagnosed in advanced stage of disease. Unfortunately at this stage, prognosis is very poor. Bevacizumab is a monoclonal antibody against VEGF, which inhibits the angiogenesis in malignant tumors. Although Bevacizumab has been approved for firstline use in advanced non-SCLC, the first report has been available for its use in SCLC. In this review, we summarized all available data on the use of Bev in SCLC patients. Finally, future directions are discussed.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26548757     DOI： 10.2174/1568009616666151106120716

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN： 1568-0096            Impact factor:   3.428


  3 in total

1.  Inter-heterogeneity and intra-heterogeneity of αvβ3 in non-small cell lung cancer and small cell lung cancer patients as revealed by 68Ga-RGD2 PET imaging.

Authors:  Fei Kang; Zhe Wang; Guoquan Li; Shengjun Wang; Daliang Liu; Mingru Zhang; Mingxuan Zhao; Weidong Yang; Jing Wang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-12       Impact factor: 9.236

2.  Bevacizumab in small cell lung cancer.

Authors:  Giandomenico Roviello; Navid Sobhani; Daniele Generali
Journal:  Ann Transl Med       Date:  2017-09

Review 3.  Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.

Authors:  Ying-Ying Liu; Tao Chen; Dan Shen; Wei-Yun Zhang; Chang-Guo Wang; Jun-Hong Jiang; Da-Xiong Zeng
Journal:  J Int Med Res       Date:  2019-12-18       Impact factor: 1.671
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.